Advertisement
The presentation will be available as a webcast athttp://www.wsw.com/webcast/jeff26/transcept.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical companyderiving significant new patient benefits from proven CNS drugs. Transceptdevelopment projects leverage new understanding of CNS conditions to provideadditional uses and enhanced clinical benefits for existing active agents. Thelead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublinguallozenge), is a low dose formulation of zolpidem for the treatment of insomniain patients who awaken in the middle of the night and have difficultyreturning to sleep. Phase 3 clinical trials have been completed forIntermezzo(R) and Transcept plans to submit an NDA in the third quarter of2008. Transcept is also developing TO-2060, a novel, fixed-dose combination ofolanzapine and ondansetron for the treatment of dopamine associatedpsychiatric disorders. For further information, please visit the company'swebsite at: www.transcept.com.Contacts: Transcept Pharmaceuticals, Inc. The Ruth Group Michael Gill Investors/Media Director of Communications Stephanie Carrington/Jason Rando (510) 215-3575 (646) 536-7017 / 7025 [email protected] [email protected] [email protected]
SOURCE Transcept Pharmaceuticals, Inc.
